Nutex health reports fourth quarter and full year 2024 financial results

Full year 2024 highlights: total revenue of $479.9 million versus $247.6 million in 2023, an increase of 93.8% net income of $52.2 million versus net loss of $45.8 million in 2023 diluted eps of $9.71 per share versus $(10.39) per share in 2023 ebitda of $98.4 million versus $(22.5) million in ebitda in 2023 adjusted ebitda of $123.7 million versus $10.8 million in 2023, an increase of 1,045.4% net cash from operating activities of $23.2 million company believes its arbitration efforts, through the independent dispute resolution (idr) process, has resulted in more equitable payments houston , march 31, 2025 /prnewswire/ -- nutex health inc. ("nutex health" or the "company") (nasdaq: nutx), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals and hospital outpatient departments (hopds) in 11 states and primary care-centric, risk-bearing physician networks, today announced fourth quarter 2024 and fiscal year 2024 financial results for the twelve months ended december 31, 2024. financial highlights for the year ended december 31, 2024: total revenue increased $232.3 million to $479.9 million for the year ended december 31, 2024 as compared to total revenue of $247.6 million for the same period in 2023, an increase of 93.8%.
NUTX Ratings Summary
NUTX Quant Ranking